New targeted drug combo aims to fight rare lymphoma
NCT ID NCT06947967
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether adding the targeted drug tucidinostat to standard CHOP chemotherapy helps people with a rare form of lymphoma called peripheral T-cell lymphoma with TFH phenotype. About 224 newly diagnosed adults will receive either tucidinostat or a placebo along with CHOP. The main goal is to see if the combination delays cancer progression or relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tucidinostat (a type of targeted cancer drug) combined with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone)
- What this could lead to
- If successful, this combination could become a new standard first-line treatment for this rare lymphoma, potentially delaying disease progression and improving survival.
- What could go wrong
- This is an early-phase 3 trial, so results are not yet known. Adding tucidinostat to chemotherapy may increase side effects, and the benefit over standard CHOP alone is unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510050, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Promising combo tackles rare blood cancer in chinese patients
- New drug cocktail aims to tackle rare blood cancer
- New pill shows promise for rare blood cancer in Late-Stage trial
- New drug combo shows promise for rare lymphoma in Real-World study
- Massive T-Cell lymphoma database aims to unlock new insights
- Promising combo for rare lymphoma hits roadblock: trial ends early